Let's Win Pancreatic CancerPancreatic

Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer Patients (Part 1/2)

In short

A 2019 study found that pancreatic cancer patients with advanced disease who have HR-DDR gene mutations live significantly longer when treated with platinum-based chemotherapy — a median of 2.37 years versus 1.45 years without it. About 17 percent of pancreatic cancer patients carry these mutations, and lead researcher Dr. Michael Pishvaian explains why getting tested matters and what the findings could mean for treatment decisions.

  • •Ask your oncologist about genetic testing for HR-DDR mutations — the National Comprehensive Cancer Network recommends hereditary cancer testing for all pancreatic cancer patients.
  • •If you have advanced pancreatic cancer and an HR-DDR mutation, ask specifically whether platinum-based therapy should be part of your treatment plan.
  • •Having an HR-DDR mutation does not automatically mean a better outlook — the survival benefit only appears when platinum therapy is used, so the mutation alone is not reassuring without treatment.
  • •If platinum therapy wasn't included in your first-line treatment, ask your doctor whether it could be considered in your next line of therapy before other options are exhausted.

Ask anything about this — free, no signup

Instant answers grounded in real guidelines, not the internet.

Artyukh Igor; Flickr A subset of pancreatic cancer patients with advanced disease got some much-needed good news. According to a February 2019 study published in the Journal of Clinical Oncology, Precision Oncology , those patients with advanced disease who have a homologous recombination, DNA damage response and repair (HR-DDR) mutation may significantly benefit from treatment with platinum agents.

, Associate Professor, GI Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston. “Our DNA gets replicated every time a cell divides and that replication can be prone to error—but these errors are normally quickly corrected by the HR-DDR process,” Pishvaian says. “However, HR-DDR mutations can occur in pancreatic tumors, weakening the ability of the cancer cell to repair DNA damage.

” About 17 percent of pancreatic cancer patient tumors harbor some form of HR-DDR mutation. Where Platinum-Based Therapy Can Be Effective The study analyzed data from 822 participants in the Know Your Tumor® program, a collaborative effort between the Pancreatic Cancer Action Network and Perthera , a precision medicine company.

In the study, Pishvaian and colleagues grouped patients into several subsets, including: Resected (surgical) patients compared to those with advanced disease. Patients with HR-DDR mutations compared to those who were DNA damage response-proficient (meaning they did not have any mutations). Those who received platinum-based treatment at any point in time compared to those who did not receive any platinum-based treatment.

“There have been a lot of studies showing that patients with HR-DDR mutations do better in terms of living longer if they receive platinum therapy and PARP inhibitors,” says Pishvaian. “But we wanted to answer some questions about the biology of HR-DDR mutations. ” Here’s what researchers found: Patients whose tumors harbor an HR-DDR mutation do not have a more favorable outcome compared to patients without such a mutation.

8 years in the mutated patients. 75 years. 2 years for those without mutations. Patients with HR-DDR mutations who receive platinum therapy have improved survival, and in particular, survival is greatly improved for those with advanced disease. 37 years.

Finding out that there is no overall survival benefit for patients with or without these mutations in the absence of platinum treatment was very important since the “study showed there was no pure prognostic value in the mutation(s) alone,” Pishvaian says. “But for patients with advanced disease with mutations who were treated with platinum therapy it’s very significant in terms of improved survival.

” The National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology in 2018 recommending hereditary cancer testing for all pancreatic cancer patients. “We’re going to see more patients who will benefit from platinum-based therapy or other targeted therapies and those are important steps in the right direction for a significant number of patients,” Pishvaian notes.

He estimated that about half of patients with advanced disease receive first-line therapy that does not include a platinum-based drug; of this group, only about half of them will receive any second-line therapy. “So that’s at least 25 percent of patients with HR-DDR mutations who aren’t getting platinum therapy, and this study shows that should change,” he adds. What’s Next? The next step is to try to answer some outstanding questions.

“For the subgroup of patients, about 17 percent of them, our study findings are showing some practice-changing benefits,” says Pishvaian. “But what we need to find out is whether other therapies, such as PARP inhibitors or even platinum therapy combined with PARP inhibitors, is potentially even more effective for some of these patients. That’s just one example, and we’ve got a ways to go.

” Pishvaian is heartened by some of the improvements in treatment that are already helping patients. “I’ve been in gastrointestinal cancer for about 12 years and focused primarily on pancreatic cancer for about nine of those years,” he explains. “It is just such a devastating disease that it makes me sad.

” “In the years I’ve been seeing pancreas cancer patients, we’ve gone from really suboptimal chemotherapy and dismal survival to better treatments that prolong life. I expect to see a lot of my patients feeling normal again, at least for a few months—which can be tremendously important to the patients, and their families.

And as for overall survival times, those have clearly improved too, and to be honest with you, we have come far enough that I get disappointed (by the disease, certainly not the patient), when patients don’t make it to two years, sometimes even more. ” He said he is also disappointed that “cynicism” about pancreas cancer is still prevalent.

For example, a large proportion of patients with pancreatic cancer do not receive cancer-directed treatment that may extend survival, according to a May 2019 study published in the Canadian Medical Association Journal . S. fares in comparison. “There is still a lot of misinformation about this disease,” Pishvaian says. “We have made progress for certain groups of patients, and the progress has been significant.

And, yes, we need to improve treatment and survival for all pancreatic cancer patients.

Highlights

from ASCO GI 2026 Survivor Stories January 28, 2026 • 3 Min Catching It Early and Moving Fast Managing Your Care January 22, 2026 • 3 Min PancChat Gets a New Home: A Podcast You Can Press “Play” On Ask the Doctor If you are in long-term treatment or have completed treatment, you may have concerns about what is next. Here are some questions to ask your doctor.

Want to learn more about your specific case?

Upload your medical records and ask Navis questions tailored to your diagnosis.